Published in
Taylor and Francis Group, Expert Review of Anticancer Therapy, 1(22), p. 17-25, 2022
DOI: 10.1080/14737140.2022.2017286
Links
Tools
Atezolizumab, cobimetinib, and vemurafenib as first-line treatment for unresectable metastatic BRAF V600 mutated melanoma
This paper was not found in any repository, but could be made available legally by the author.
Full text: Unavailable
Preprint: archiving forbidden
Published version:
archiving forbidden
Data provided by 